Xianjian Technology announced that the LantValTM aortic valve replacement system jointly developed by Shenzhen Jianxin Medical Technology Co., Ltd., a subsidiary of the company, and Fuwai Hospital of the Chinese Academy of Medical Sciences of the National Cardiovascular Center received an official written notice from the State Drug Administration on September 9, 2026 confirming that it has entered the special review process for innovative medical devices. It is the company's 18th product to enter this procedure; currently, pre-marketing registration clinical research is about to begin.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.